Indivior Pharmaceuticals Inc
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Joseph J. Ciaffoni
- Full Time Employees
- 833
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 10710 Midlothian Turnpike North Chesterfield VA United States of America 23235
- IPO Date
- Dec 29, 2014
- CIK
- 0001625297
- Website
- indivior.com
- Similar Companies
- Business
- Indivior PLC develops, manufactures and commercializes prescription medicines focused on treating opioid use disorder and other serious mental illnesses; its core products include SUBLOCADE (buprenorphine extended-release injection), PERSERIS (risperidone extended-release injectable suspension for schizophrenia), SUBOXONE (buprenorphine/naloxone sublingual film and tablet), OPVEE (naloxone nasal spray for opioid overdose reversal), and pipeline candidates such as INDV-2000 (selective orexin-1 receptor antagonist in Phase 2 for OUD) and INDV-6001 (buprenorphine-based long-acting injectable developed with Alar Pharmaceuticals Inc.). The company, founded in 2014 as a spin-off from Reckitt Benckiser and headquartered in North Chesterfield, Virginia, operates primarily in the United States, United Kingdom and over 30 other countries worldwide, generating the majority of its revenue from the U.S. market where it holds approximately 30% share in opioid dependency treatments. In recent developments, Indivior raised its full-year 2025 revenue guidance to $1.03-$1.08 billion following strong Q3 2025 results with SUBLOCADE net revenue up 15% year-over-year; launched the Indivior Action Agenda to optimize operations, simplify its business model and deliver at least $150 million in annual expense savings starting 2026; completed refinancing of its secured term loan with six-year facilities to extend maturity and improve liquidity; moved its primary stock listing to Nasdaq in July 2025 after canceling its London Stock Exchange secondary listing; appointed Patrick Barry as Chief Commercial Officer in May 2025 to enhance SUBLOCADE commercialization; proposed a U.S. redomiciliation via a scheme of arrangement to establish Indivior Pharmaceuticals Inc. as the new U.S. parent company effective late January 2026, aiming to expand U.S. capital markets presence and simplify governance; announced a $100 million share repurchase program in June 2024; received BARDA's first order for OPVEE in 2024; concluded a legacy U.S. Department of Justice matter in November 2025; and included in Russell 2000 and 3000 indexes in June 2025.
Company News
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV)
Supernus Pharmaceuticals (SUPN) Announces Transformative Merger with Indivior (INDV)
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Indivior Pharmaceuticals Inc. (INDV) Q2 Earnings and Revenues Beat Estimates
Supernus, Indivior merge to strengthen neuroscience drug portfolio
Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
Indivior to Report Second Quarter 2026 Financial Results and Host Webcast
Billionaire Investor Howard Marks' Top 5 Holdings: A Buy at These Prices?
Indivior Pharmaceuticals Inc. (INDV) is on the Move, Here's Why the Trend Could be Sustainable
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
Indivior's Chief Scientific Officer Sold Over 18,000 Company Shares. Should Investors Worry?